Abstract: Conjugated linoleic acid (CLA) is known to modulate lipid and lipoprotein metabolism. We examined the effects of dietary CLA (1 and 2%) on hepatic microsomal triacylglycerol transfer protein (MTP) activity, known to be essential for the assembly/secretion of the apolipoprotein B-containing lipoproteins, and lipid concentrations of liver and plasma in OLETF obese rats. A significant reduction in hepatic MTP activity in CLA-fed rats in comparison to rats fed a linoleic acid (LA) diet was noted. Hepatic and serum triacylglycerol (TAG) concentrations were lowered in the CLA groups as compared to the control LA group. Decreased serum insulin and leptin levels were seen in the CLA groups. These results indicate that dietary CLA reduces both hepatic MTP activity and TAG content, and therefore reduces hepatic lipoprotein assembly and secretion.
Introduction
The term of CLA refers to a group of positional and geometric isomers of linoleic acid that are found in milk, pasteurized dairy products and ruminant meats (1) (2) (3) . CLA has received considerable attention due to a number of biological activities (4) (5) (6) (7) (8) (9) (10) , and showed antiobesity (8) (9) (10) and anti-atherogenic (6) activities. We previously reported that administration of the 10trans,12cis-CLA isomer inhibits the secretion of apolipoprotein B100 and TAG in HepG2 human liver derived cells (11) . We also noted that CLA reduces abdominal fat weights and serum TAG concentration in obese rats (12, 13) . This suggests that CLA inhibits of lipoprotein assembly and secretion.
MTP plays a crucial role in the assembly and secretion of apolipoprotein B containing lipoproteins, in particular very low density lipoprotein (VLDL) (14, 15) . MTP is a heterodimeric protein containing subunits of molecular mass 97 kDa and 58 kDa (16) . The 97 kDa subunit possesses the lipid transfer activity (16) , while the 58 kDa component of MTP is a multifunctional protein, protein disulfide isomerase (17) . Defects in MTP causes abetalipoproteinemia, a rare human genetic disease characterized by defects in VLDL and chylomicron assembly (18, 19) . Little is known, however, of the effects of CLA on MTP activity on in vivo hepatic lipoprotein assembly/secretion.
In the present study, we investigated the effect of dietary TAG-form of CLA on hepatic MTP activity and
lipid mass in OLETF rats, an animal model of noninsulin dependent diabetes mellitus (NIDDM), which develops hypertriglyceridemia at an early stage and shows glucose intolerance with hyperinsulinemia in adulthood (20) . [ 14 C]Triolein (specific activity, 55 mCi / mmol) was purchased from American Radiolabeled Chemicals, Inc., St. Louis, USA. The CLA and safflower oil were provided by Rinoru Oil Mills (Nagoya, Japan). All other chemicals were of best analytical grade available.
Materials and Methods

1 Experimental Material and Reagents
Animals and Diets
Male OLETF rats were donated from Tokushima Research Institute (Otsuka Pharmaceutical Co. Ltd., Tokushima, Japan) and were housed individually in stainless cages in a room (23 1 ) under a 12-h light/12-h dark cycle (lights on from 7.00 A.M. to 19.00 P.M.). After one week of adaptation period, the rats were divided into three groups and fed the following test diets for 4 weeks. The control diet was prepared by supplemented 6.5% linoleate (LA)-rich safflower oil to basal diet (LA diet). CLA (TAG-CLA) was added to the LA diet at the expense of safflower oil at the 1 and 2 % level (CLA-diet). The basal diet was composed of 20% casein, 0.3% DL-methionine, 3.5% mineral mixture (AIN 93), 1% vitamin mixture (AIN 93), 0.2% choline bitartarate, 5% cellulose, 6.5% safflower oil and sucrose to make 100%. The composition of experimental diets used is given in Table 1 . The CLA was a mixture of different isomers as 33.2% c-9,t-11/t-9,c-11 and 34.2% t-10,c-12. Fresh diet was provided every day and all rats had free excess to both experimental diets and water. Food intake was recorded every day, while body weight was recorded on every other day. After the experimental period of 4 weeks, rats were sacrificed following 8-h fasting. Blood collected from the venacava and various tissues were collected and kept frozen at -80 until analyses. The animal experiment was conducted according to the guideline provided by the ethical committee of experimental animal care at Saga University.
3 Measurement of Serum and Liver
Metabolites Hepatic lipids were extracted, purified and lipid concentrations were measured as described in our previous studies (21, 22) . TAG, total cholesterol, HDL-cholesterol and phospholipid in serum were measured with commercial kits supplied by Wako Pure Chemical Ind. (Osaka, Japan) following the procedure outlined. Seum leptin and insulin concentrations were measured as described previously (21).
4 Preparation of Tissue Homogenates
and Sub Cellular Fractions Liver homogenates and subcellular fractions were prepared as described previously (21, 22) . Protein was measured by the method of Lowry et al. (23) .
5 MTP Assay
MTP activity was determined by measuring the transfer of radiolabeled triacylglycerol between two populations of unilamellar vesicles as described (11) . Radioactivity was measured with a liquid scintillation counter (Wallac system 1410, Pharmacia, Turku, Finland).
6 Statistical Analyses
All values are presented as means SE. Data were analyzed by one-way analysis of variance (ANOVA), followed by inspection of all differences by Duncan's new multiple-range test (24) . Differences were considered significant at p< 0.05. 
1 Growth Parameters
Supplementation of CLA as TAG-form at levels of 1% and 2% levels reduced weight gain slightly but significantly, compared to the control LA group (Fig. 1) . Dietary food intake was comparable between groups (LA group 25.5 g/day, CLA groups 24.8 g/day). CLA had no effect on liver weight. In contrast, CLA supplementation lowered abdominal adipose tissue weights in both CLA groups, in agreement with previous reports (12, 13) . These results suggest that the intake of CLA was responsible for reduction in body weight in the CLA groups.
2 Liver and Serum Lipid Metabolites
CLA supplementation induced a significant decrease in hepatic TAG levels (Fig. 2) , whereas hepatic phospholipid and cholesterol levels were comparable between groups (data not shown). A significant dosedependent reduction in serum TAG concentration was seen with CLA diets (Fig. 2) . Dietary CLA did not, however, produce any significant changes in the serum concentrations of cholesterol and phospholipid. CLA supplementation also lowered serum insulin levels in a dose-dependent manner (Fig. 3) . Serum leptin levels were decreased by the administration of CLA (Fig. 3) .
There is therefore a positive correlation between alterations in adipose tissue weight and serum leptin levels.
Liver MTP Activity
CLA supplementation reduced hepatic MTP activity significantly (40%) in comparison with the LA group (Fig. 4) . A positive correlation was seen between MTP activity and hepatic TAG mass. The reduction in MTP activity with dietary CLA was also associated with a reduction in serum TAG.
Discussion
The present study showed that CLA supplementation reduces hepatic MTP activity, and hepatic and serum TAG levels in OLETF rats. The production of VLDL in the liver depends on biosynthesis of apolipoprotein B and lipids, assembly of the lipoprotein particle, and secretion of the mature VLDL into blood. Hepatic assembly and secretion of apolipoprotein B-containing lipoprotein is thought to be a two steps process. The first step involves the MTP-facilitated formation of a nascent lipoprotein particle in the endoplasmic reticulum. The second step requires ADP-ribosylation factor 1, and facilitates the apparent fusion of the nascent lipoprotein particle with apolipoprotein B-free core (25, 26) .
Apolipoprotein B is transcribed constitutively and its secretion is primarily regulated at the posttranscriptional level (27) . A significant portion of newly synthesized apolipoprotein B is targeted for intracellular degradation (28, 29) . Lipidation of newly synthesized apolipoprotein B appears to prevent its degradation. In the presence of MTP and adequate supply of intracellular lipid supply, cotranslational lipoprotein assembly is initiated within cells (30, 31, 32) . Treatment of hepatocytes with an MTP inhibitor reduces the secretion of apolipoprotein B and TAG (33) . It is therefore assumed that alterations MTP activity may affect VLDL assembly and therefore lipoprotein production.
In the present study, a significant reduction in hepatic MTP activity in OLETF rats following CLA supplementation was noted. We also found CLA decreases hepatic and serum TAG concentrations. A positive correlation (r = 0.65) was also seen between hepatic MTP activity and serum TAG concentrations. Kuriyama et al. (34) and our group (Wang et al., in preparation) have found enhanced expression of hepatic MTP mRNA level in OLETF rats. The reduction in MTP mRNA expression with dietary CLA seems to be associated with decreased MTP activity in OLETF rats.
Decreases in hepatic MTP activity and serum TAG concentration with the administration of CLA as seen in the present study may be important in the prevention and treatment of hypertriglyceridemia. There are several possible mechanisms by which CLA may reduce hepatic MTP activity and lipid mass. In our previous studies, CLA was found to stimulate carnitine palmitoyltransferase (CPT) activity in the liver, white adipose tissue, and muscle, suggesting that CLA induces fatty acid beta-oxidation in the body. CLA also decreased the activity of fatty acid synthase in the liver. The metabolic alteration of these enzymes by CLA treatment was also confirmed at the level of mRNA expression (35) . We further demonstrated that treatment with the 10trans,12cis-CLA isomer reduces the secretion of apolipoprotein B100 and TAG in human liver model Hep G2 cells. In addition, CLA reduces plasma nonesterified fatty acid in rats may lead to decreased availability of fatty acid for TAG synthesis in the liver. Under the experimental conditions of this study, it was confirmed that CLA induces a reduction of white adipose tissue mass (8, 9) . CLA actually reduces the mRNA expression of fatty acid synthase, and also SREBP-1c, a key regulator of lipid metabolism. The reduced availability of TAG demonstrated in the present study as a consequence of CLA feeding may indicate the down-regulation of MTP mRNA expression (35) .
MTP mRNA expression is regulated by dietary (36, 37) and hormones factors (38). Insulin inhibits hepatic mRNA level in HepG2 cells (38) . It is known that OLETF rats have hyperinsulemia (7-fold) compared to the lean rats. In the present study, dietary CLA tended to reduce serum insulin concentration in a dose-dependent manner. It is possible to ascertain the impact of insulin hepatic MTP activity in the present study.
Peroxisome proliferator-activated receptors (PPARs), the nuclear receptor superfamily (39, 40) , are likely to be involved in the action of CLA isomers. Moya-camerena et al. reported that CLA administration activated PPARa (41). Houseknecht et al. showed that a mixture of CLA isomers activates PPARg in vitro, and normalized impaired glucose tolerance in diabetic rats (42) . In this context, we recently demonstrated that the 10trans,12cis-CLA isomer, but not the 9cis,11trans-CLA isomer, down-regulates the expression of SREBP1c (35) , that plays a critical role in the regulation of hepatic lipogenic genes (43) . The roles of these transcriptional regulators on the actions of CLA action remained to be studied.
In summary, dietary CLA decreases hepatic MTP activity and TAG concentrations in OLETF obese rats, which may be responsible for the reduction in serum TAG.
